{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:30:53Z","timestamp":1774686653870,"version":"3.50.1"},"reference-count":28,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej12-0427","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T23:08:58Z","timestamp":1370992138000},"page":"977-983","source":"Crossref","is-referenced-by-count":28,"title":["Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile"],"prefix":"10.1507","volume":"60","author":[{"given":"Yenna","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea"},{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Joo","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa Young","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Ah","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Un","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hee","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea"},{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Joon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Chul","family":"Oh","sequence":"additional","affiliation":[{"name":"Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hak C.","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea"},{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka Hee","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea"},{"name":"Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yaturu S, Prado S, Grimes SR (2004) Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. <i>J Cell Biochem<\/i> 93: 491-496.","DOI":"10.1002\/jcb.20188"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Oge A, Bayraktar F, Saygili F, Guney E, Demir S (2005) TSH influences serum leptin levels independent of thyroid hormones in hypothyroid and hyperthyroid patients. <i>Endocr J<\/i> 52: 213-217.","DOI":"10.1507\/endocrj.52.213"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Iglesias P, Alvarez Fidalgo P, Codoceo R, Diez JJ (2003) Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. <i>Clin Endocrinol (Oxf)<\/i> 59: 621-629.","DOI":"10.1046\/j.1365-2265.2003.01897.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Aragao CN, Souza LL, Cabanelas A, Oliveira KJ, Pazos-Moura CC (2007) Effect of experimental hypo- and hyperthyroidism on serum adiponectin. <i>Metabolism<\/i> 56: 6-11.","DOI":"10.1016\/j.metabol.2006.08.015"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, et al. (2011) Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. <i>Mol Med<\/i> 17: 736-740.","DOI":"10.2119\/molmed.2011.00075"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. (2012) <i>Genes Dev<\/i> 26: 271-281.","DOI":"10.1101\/gad.177857.111"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chen WW, Li L, Yang GY, Li K, Qi XY, et al. (2008) Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. <i>Exp Clin Endocrinol Diabetes<\/i> 116: 65-68.","DOI":"10.1055\/s-2007-985148"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Eto K, Tumenbayar B, Nagashima S, Tazoe F, Miyamoto M, et al. (2010) Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. <i>Diabetes Res Clin Pract<\/i> 89: 52-57.","DOI":"10.1016\/j.diabres.2010.03.019"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cuevas-Ramos D, Almeda-Valdes P, Aguilar-Salinas CA, Cuevas-Ramos G, Cuevas-Sosa AA, et al. (2009) The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism. <i>Curr Diabetes Rev<\/i> 5: 216-220.","DOI":"10.2174\/157339909789804396"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mai K, Schwarz F, Bobbert T, Andres J, Assmann A, et al. (2011) Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. <i>Metabolism<\/i> 60: 306-311.","DOI":"10.1016\/j.metabol.2010.02.016"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Li H FQ, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W (2010) Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. <i>J Hepatol<\/i> 53: 934-940.","DOI":"10.1016\/j.jhep.2010.05.018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Morris-Stiff G Feldstein AE (2010) Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. <i>J Hepatol<\/i> 53: 795-796.","DOI":"10.1016\/j.jhep.2010.07.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. <i>Diabetes<\/i> 57: 1246-1253.","DOI":"10.2337\/db07-1476"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Adams AC, Astapova I, Fisher FM, Badman MK, Kurgansky KE, et al. (2010) Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner. <i>J Biol Chem<\/i> 285: 14078-14082.","DOI":"10.1074\/jbc.C110.107375"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. <i>Endocrinology<\/i> 149: 6018-6027.","DOI":"10.1210\/en.2008-0816"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. <i>Diabetes<\/i> 58: 250-259.","DOI":"10.2337\/db08-0392"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chen C, Cheung BM, Tso AW, Wang Y, Law LS, et al. (2011) High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. <i>Diabetes Care<\/i> 34: 2113-2115.","DOI":"10.2337\/dc11-0294"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, et al. (2011) Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. <i>Diabetes Metab Res Rev<\/i> 27: 286-297.","DOI":"10.1002\/dmrr.1177"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, et al. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. <i>Cell Metab<\/i> 5: 426-437.","DOI":"10.1016\/j.cmet.2007.05.002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, et al. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. <i>Cell Metab<\/i> 5: 415-425.","DOI":"10.1016\/j.cmet.2007.05.003"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, et al. (2012) Fibroblast Growth Factor-21 Regulates PPARgamma Activity and the Antidiabetic Actions of Thiazolidinediones. <i>Cell<\/i> 148: 556-567.","DOI":"10.1016\/j.cell.2011.11.062"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, et al. (2007) Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. <i>J Cell Physiol<\/i> 210: 1-6.","DOI":"10.1002\/jcp.20847"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. al-Adsani H, Hoffer LJ, Silva JE (1997) Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. <i>J Clin Endocrinol Metab<\/i> 82: 1118-1125.","DOI":"10.1210\/jc.82.4.1118"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Adamson LF, Ingbar SH (1967) Selective alteration by triiodothyronine of amino acid transport in embryonic bone. <i>Endocrinology<\/i> 81: 1362-1371.","DOI":"10.1210\/endo-81-6-1362"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Muller MJ, Reynard CA, Burger AG, Toffolo G, Cobelli C, et al. (1995) Kinetic analysis of thyroid hormone action on glucose metabolism in man. <i>Eur J Endocrinol<\/i> 132: 413-418.","DOI":"10.1530\/eje.0.1320413"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Muller MJ, Seitz HJ (1980) Rapid and direct stimulation of hepatic gluconeogenesis by L-triiodothyronine (T3) in the isolated-perfused rat liver. <i>Life Sci<\/i> 27: 827-835.","DOI":"10.1016\/0024-3205(80)90076-4"},{"key":"27","unstructured":"27. Zhang M, Xiong ZY, Zeng L, Wang YJ, Huang MJ, et al. (2010) Plasma fibroblast growth factor-21 and abdominal obesity. <i>Sichuan<\/i><i> Da Xue Xue Bao Yi Xue Ban<\/i> 41: 218-221."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Uebanso T, Taketani Y, Yamamoto H, Amo K, Tanaka S, et al. (2012) Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet. <i>J Nutr Biochem<\/i> 23: 785-790.","DOI":"10.1016\/j.jnutbio.2011.03.023"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/8\/60_EJ12-0427\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:38:31Z","timestamp":1618295911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/8\/60_EJ12-0427\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej12-0427","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}